Small AI biotech BioX­cel surges on pos­i­tive PhI­II re­sults, set­ting up de­men­tia and Alzheimer’s test

A small biotech added a few hun­dred mil­lion dol­lars in mar­ket val­ue Mon­day morn­ing af­ter an­nounc­ing pos­i­tive Phase III re­sults from their lead neu­rol­o­gy drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER